A number of studies have already confirmed that those dealing with Parkinson’s can find relief in cannabis
With medical marijuana now legalized in more than 30 states, it is obvious that there is great interest in its therapeutic properties. Researchers are testing marijuana as a treatment for many diseases, including neurological conditions such as Parkinson’s disease. The latest to show this interest was Gb Sciences, a biopharmaceutical research and drug development firm. Its recently published study demonstrates the efficacy of its proprietary minimal essential mixtures containing cannabinoids for the treatment of this condition.
The research has been able to demonstrate that cannabinoids can mitigate non-motor symptoms of Parkinson’s disease, such as perceptual disorders and other dysfunctions of the autonomic nervous system, which could become a powerful ally against this disease. Researchers began to show enthusiasm for studying cannabis in relation to Parkinson’s after people with Parkinson’s reported their anecdotes and posted on social networks how cannabis supposedly reduced their tremors.
Cannabinoids were shown to have sufficient effects in treating several symptoms, such as bradykinesia (slowness caused by Parkinson’s) and dyskinesia (excess movement caused by levodopa). Gb Sciences president and CSO Andrea Small-Howard said the drug discovery process has identified promising mixtures for the treatment of this disease in an animal model of the disease.
She added, “This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics.” While results such as these have been positive, the effects of medical marijuana are probably not fully understood, so more studies are needed, especially those with more subjects.